Compare · OMIC vs PKI
OMIC vs PKI
Side-by-side comparison of Singular Genomics Systems Inc. (OMIC) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OMIC and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- PKI is the larger of the two at $21.38B, about 43.8x OMIC ($487.8M).
- PKI has more recent analyst coverage (17 ratings vs 5 for OMIC).
- Company
- Singular Genomics Systems Inc.
- PerkinElmer Inc.
- Price
- $19.98+0.35%
- $115.23-0.88%
- Market cap
- $487.8M
- $21.38B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 17
Singular Genomics Systems Inc.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
PerkinElmer Inc.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Latest OMIC
- Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)
- Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.
- Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Glezer Eli N. returned 155,583 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operating Officer Ghai Jyotsna returned 3,283 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Ryan Jason
- Director Pellini Michael J returned 351,222 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Mardis Elaine R
Latest PKI
- Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)
- Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Klobuchar Michael A was granted 481 shares (SEC Form 4)
- Vandebroek Sophie V. was granted 481 shares (SEC Form 4)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- Singh Prahlad R. exercised 57,039 shares at a strike of $76.83, sold $2,212,480 worth of shares (21,217 units at $104.28) and covered exercise/tax liability with 15,424 shares, increasing direct ownership by 25% to 103,414 units (SEC Form 4)
- Victor Miriame exercised 2,408 shares at a strike of $105.62 and covered exercise/tax liability with 1,030 shares, increasing direct ownership by 15% to 10,470 units (SEC Form 4)